Our Studies
| Indication | Therapeutic Area | No. of Patients | No. of Study |
| Gastroenterology | Ulcerative Colitis | 32 | 3 |
| Crohn’s Disease | 11 | 2 | |
| GERD | 43 | 2 | |
| NAFLD | 68 | 2 | |
| Oncology | Breast Cancer | 12 | 1 |
| Ovarian Cancer | 9 | 1 | |
| Endocrinology | Diabetes Type II | 98 | 4 |
| Diabetes Type I | 32 | 2 | |
| Thyroid | 45 | 2 | |
| Rheumatology | Rheumatoid Arthritis | 58 | 3 |
| Ankylosing Spondylitis | 49 | 2 | |
| SLE | 17 | 2 | |
| Osteoarthritis | 54 | 2 | |
| Pulmonology | COPD | 27 | 2 |
| Asthma | 35 | 2 | |
| Eosinophilic Asthma | 17 | 1 | |
| Psychiatry | Schizophrenia | 28 | 2 |
| Bipolar Disorder | 26 | 1 | |
| Depression | 48 | 2 | |
| Dermatology | Acne Vulgaris | 21 | 3 |
| Atopic Dermatitis | 24 | 2 | |
| Psoriasis | 28 | 2 | |
| Vaccine | COVID 19 | 1400 | 1 |
| Cardiology | Heart Failure | 22 | 1 |
| Neurology | Multiple Sclerosis | 13 | 1 |
| Parkinson's Disease | 12 | 1 | |
| Ophthalmology | Glaucoma | 34 | 1 |
| WET AMD | 55 | 3 |
Latest Achievements
A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease
A randomised, double blind, parallel, interventional phase IIa proof of concept trial to evaluate the efficacy and safety of ZYIL1 for the treatment of patients with mild to moderately active Ulcerative Colitis resistant or intolerant to oral amino salicylates
A Phase III, Randomized, Double blind, Parallel Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity between Test Aflibercept and Eylea® in Patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD)
A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2)
A study to check out the effectiveness and safety of Lumateperone as another treatment used together with the main treatment in the Treatment of Patients with Major Depressive Disorder
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis
A Multicenter, Randomized, Placebo and Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects from 6 to less than 18 Years of Age with Moderate to Severe Chronic Plaque Psoriasis
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 2)
Evaluate the effectiveness and safety of Elidel® in infants and children affected by mild to moderate Atopic dermatitis (AD) in India
A phase 2 randomized, double-blind, parallel-group, placebo and active-controlled, two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naïve patients with moderate to severely active ulcerative colitis
A phase 3, multicenter, randomized, double-blind, double- dummy, parallel-group study to compare the efficacy and safety of fixed dose combination tablets of Dapagliflozin 10 mg and Linagliptin 5 mg versus Trajenta 5 mg(Linagliptin 5 mg) in patients with Type 2 Diabetes Mellitus(T2DM) inadequately controlled on Metformin
A Phase 4, open-label, single arm, 24-week, phase 4 study to evaluate the safety and efficacy of Mepolizumab 100 mg SC administered every 4 weeks in Indian participants aged ≥18 years with Severe eosinophilic asthma requiring oral corticosteroid treatment to Maintain asthma control (PRISM)